Phase 2a (ABT-606) • Ucensed to Reliant Pharmaceuticals -developed tablet formulation (RP-606) • Ucensed to Epiphany Biosciences - completed key Shingles & EBV proof-of.concept Phase 2 studies Proven antiviral activity, dinical impact, & safety in multiple Phase 1 & 2 trials • Successful Phase 2b trial for shingles met primary en